AR076014A1 - Derivados de 3- (1,4) oxazepan -4-pirimidona - Google Patents
Derivados de 3- (1,4) oxazepan -4-pirimidonaInfo
- Publication number
- AR076014A1 AR076014A1 ARP100101059A ARP100101059A AR076014A1 AR 076014 A1 AR076014 A1 AR 076014A1 AR P100101059 A ARP100101059 A AR P100101059A AR P100101059 A ARP100101059 A AR P100101059A AR 076014 A1 AR076014 A1 AR 076014A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- hydrogen atom
- alkyl group
- atom
- alkyl
- Prior art date
Links
- AQNQGBUEVCAVML-UHFFFAOYSA-N oxazepane Chemical compound C1CCNOCC1 AQNQGBUEVCAVML-UHFFFAOYSA-N 0.000 title 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 8
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000000041 C6-C10 aryl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 208000013403 hyperactivity Diseases 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- -1 oxazepan-4-pyrimidone Chemical compound 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 108010061506 tau-protein kinase Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Derivados de 3-[1,4]oxazepan-4-pirimidona que se usa para el tratamiento preventivo y/o terapéutico de una enfermedad provocada por la hiperactividad de tau proteína cinasa 1 tales como enfermedades neurodegenerativas (por ejemplo, la enfermedad de Alzheimer). Reivindicacion 1: Un compuesto representado por la formula (1) o una sal farmacéuticamente aceptable de él, en donde Z representa un átomo de nitrogeno o C-X; X representa un átomo de hidrogeno o un átomo de halogeno; R1 representa un grupo alquilo C1-3; Y representa un átomo de oxígeno o N-R7; R2, R3, R4, R5, R6 y R7 pueden ser iguales o diferentes y cada uno representa un átomo de hidrogeno, un grupo alquilo C1-6, o un grupo representado por la formula (2) en donde R8 representa un átomo de hidrogeno, un átomo de halogeno, un grupo ciano, un grupo nitro, un grupo alquilo C1-6, o un grupo representado por cualquiera de las formulas (IIIa) a (IIIh) del grupo de formulas (3) en donde R9 representa un átomo de hidrogeno o un grupo alquilo C1-6; R11, R13, R14, R15, R16, R17, R18, R19 y R20 pueden ser iguales o diferentes y cada uno independientemente representa un átomo de hidrogeno, un grupo alquilo C1-6, o un grupo arilo C6-10; R12 representa un átomo de hidrogeno, un grupo hidroxilo, amino, alquilo C1-6, alquiloxi C1-3, alquilamino C1-3, un grupo di-alquilo C1-3-amino, o un grupo arilo C6-10; R10 representa un átomo de hidrogeno o un grupo representado por la siguiente formula: -A-R21 en donde A representa -(CH2)p-, -CO-, o -SO2-, en donde p representa un numero entero de 1 a 3; R21 representa un átomo de hidrogeno, un grupo alquilo C1-3, -OR22, -NR23R24, o un grupo arilo C6-10; en donde R22, R23 y R24 pueden ser iguales o diferentes y cada uno independientemente representa un átomo de hidrogeno, un grupo alquilo C1-6, alquenilo C1-6, o un grupo aril-metilo C6-10; o R10 y R11 se pueden combinar uno con otro para formar un anillo heterocíclico junto con el átomo de nitrogeno al cual se unen R10 y R11.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009105674 | 2009-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR076014A1 true AR076014A1 (es) | 2011-05-11 |
Family
ID=42221793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100101059A AR076014A1 (es) | 2009-04-02 | 2010-03-31 | Derivados de 3- (1,4) oxazepan -4-pirimidona |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9108957B2 (es) |
| EP (1) | EP2414349A1 (es) |
| JP (1) | JP5728633B2 (es) |
| AR (1) | AR076014A1 (es) |
| TW (1) | TW201100407A (es) |
| WO (1) | WO2010114179A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2193129B1 (en) | 2007-09-14 | 2012-10-24 | Mitsubishi Tanabe Pharma Corporation | 6-pyrimidinyl-pyrimid-2-one derivative |
| EP2464632A1 (en) | 2009-08-13 | 2012-06-20 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| EP2464639A1 (en) | 2009-08-13 | 2012-06-20 | Mitsubishi Tanabe Pharma Corporation | Pyrimidone derivatives used as tau protein kinase 1 inhibitors |
| JP5603487B2 (ja) | 2010-06-10 | 2014-10-08 | テクニオン リサーチ アンド ディベラップメント ファウンデイション リミテッド | ヨウ化物の調製のためのプロセス |
| US9526720B2 (en) | 2012-08-17 | 2016-12-27 | The Broad Institute, Inc. | Modulators of hepatic lipoprotein metabolism |
| WO2019209759A1 (en) * | 2018-04-24 | 2019-10-31 | Merck Patent Gmbh | Antiproliferation compounds and uses thereof |
| WO2025223536A1 (zh) * | 2024-04-26 | 2025-10-30 | 正大天晴药业集团股份有限公司 | 稠合双环化合物及其用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2116460A1 (en) | 1993-03-02 | 1994-09-03 | Mitsubishi Chemical Corporation | Preventive or therapeutic agents for alzheimer's disease, a screening method of alzheimer's disease and tau-protein kinase i originated from human being |
| TWI241298B (en) | 1998-09-25 | 2005-10-11 | Mitsubishi Chem Corp | Pyrimidone derivatives |
| EP1136482A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| EP1136483A1 (en) | 2000-03-23 | 2001-09-26 | Sanofi-Synthelabo | 2-[Piperazinyl]pyrimidone derivatives |
| IL160700A0 (en) | 2001-09-21 | 2004-08-31 | Mitsubishi Pharma Corp | 3-substituted-4-pyrimidone derivatives |
| DE60208051T2 (de) | 2001-09-21 | 2006-06-22 | Sanofi-Aventis | 3-substituierte-4-pyrimidonderivate |
| TW200813015A (en) * | 2006-03-15 | 2008-03-16 | Mitsubishi Pharma Corp | 2-(cyclic amino)-pyrimidone derivatives |
| MX2009001913A (es) * | 2006-08-23 | 2009-03-06 | Pfizer Prod Inc | Compuestos de pirimidona como inhibidores de gsk-3. |
-
2010
- 2010-03-31 AR ARP100101059A patent/AR076014A1/es unknown
- 2010-04-01 TW TW099110182A patent/TW201100407A/zh unknown
- 2010-04-01 WO PCT/JP2010/056346 patent/WO2010114179A1/en not_active Ceased
- 2010-04-01 US US13/262,396 patent/US9108957B2/en not_active Expired - Fee Related
- 2010-04-01 EP EP10714373A patent/EP2414349A1/en not_active Withdrawn
- 2010-04-01 JP JP2011542382A patent/JP5728633B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP5728633B2 (ja) | 2015-06-03 |
| TW201100407A (en) | 2011-01-01 |
| JP2012522724A (ja) | 2012-09-27 |
| WO2010114179A1 (en) | 2010-10-07 |
| US20120095216A1 (en) | 2012-04-19 |
| EP2414349A1 (en) | 2012-02-08 |
| US9108957B2 (en) | 2015-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR076014A1 (es) | Derivados de 3- (1,4) oxazepan -4-pirimidona | |
| HUP0401784A2 (hu) | Heterobiciklikus szerkezetû virális polimeráz inhibitorok, eljárás az elõállításukra, köztitermékek és ezeket tartalmazó gyógyszerkészítmények | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR070950A1 (es) | Compuestos derivados de amina, composiciones farmaceuticas de ellos, compuestos inhibidores de produccion de 11-cis-retinol y metodos para tratar enfermedades y trastornos oftalmicos | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| EA200970510A1 (ru) | Гетеромоноциклическое соединение и его применение | |
| AR084370A1 (es) | Derivados de aminopirazol | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| PE20160844A1 (es) | Compuestos triciclicos como agentes anticancerigenos | |
| AR073314A1 (es) | Derivados de indazol o de 4,5,6,7-tetrahidro-indazol | |
| BR122012009489B8 (pt) | processo para produzir 2-etóxi-1-{[2-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso | |
| AR060604A1 (es) | Nuevos arilamino n- heteroarilos como inhibidores de mek | |
| RU2010126105A (ru) | Производные пиридина, замещенные гетероциклическим кольцом и фосфоноксиметильной группой, и содержащие их противогрибковые средства | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR062409A1 (es) | Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto | |
| CL2004000174A1 (es) | Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer. | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR065811A1 (es) | Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos. | |
| AR036604A1 (es) | Derivados de 4-pirimidona 3-sustituida | |
| AR049263A1 (es) | Heterociclos biciclicos inhibidores de quinasa utiles como agentes anticancer | |
| CO6460743A2 (es) | Derivados de 7-aza-espiro[3.5]nonano-7-carboxilatos, su preparación y su aplicación en terapéutica | |
| CO2020001326A2 (es) | Nuevos compuestos heterocíclicos como inhibidores de cdk8/19 | |
| EA201071012A1 (ru) | Производные азетидинов, способ их получения и применение их в терапии | |
| AR059018A1 (es) | Derivados de 6- fenil -1h- imidazo (4,5-c) piridina -4- carbonitrilo y su uso en el tratamiento de enfermedades relacionadas con catepsina s y/o catepsina k | |
| AR082633A1 (es) | Analogos de tetraciclina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |